ERBB2 and breast cancer: Furthermore, DS-8201a is under development in the DESTINY-Breast04 (NCT03734029), a phase 3 trial assessing this agent’s efficacy in treating patients with HER2-low breast cancer (i.e., IHC 1+ and IHC 2+/ISH- HER2-expression tumors).